FIELD: biotechnology.
SUBSTANCE: present invention relates to antibodies specifically binding to thymic stromal lymphopoietin (TSLP), and can be used in medicine for treating an inflammatory disease, associated with TSLP, selected from asthma, chronic obstructive pulmonary disease, allergic rhinitis, allergic rhinosinusitis, allergic conjunctivitis, eosinophilic oesophagitis and atopic dermatitis. Antibodies and their antigen-binding fragments, containing their compositions, methods of their application and production are offered.
EFFECT: invention enables to obtain an antibody which binds human TSLP with a dissociation constant (KD) of less than 10 pM.
50 cl, 12 dwg, 14 tbl, 20 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MOLECULES BINDING TO 4-1BB | 2011 |
|
RU2551963C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BINDING MOLECULES INDUCING CELLULAR ACTIVATION | 2019 |
|
RU2770620C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| HER-2-DIRECTED ANTIGEN-BINDING MOLECULES CONTAINING 4-1BBL | 2019 |
|
RU2815451C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| ANTI-IGE ANTIBODIES | 2017 |
|
RU2816207C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
